1. Home
  2. CRDL vs AMTD Comparison

CRDL vs AMTD Comparison

Compare CRDL & AMTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • AMTD
  • Stock Information
  • Founded
  • CRDL 2017
  • AMTD 2003
  • Country
  • CRDL Canada
  • AMTD France
  • Employees
  • CRDL N/A
  • AMTD 214
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • AMTD
  • Sector
  • CRDL Health Care
  • AMTD
  • Exchange
  • CRDL Nasdaq
  • AMTD Nasdaq
  • Market Cap
  • CRDL 90.4M
  • AMTD 93.9M
  • IPO Year
  • CRDL N/A
  • AMTD 2019
  • Fundamental
  • Price
  • CRDL $1.07
  • AMTD $1.14
  • Analyst Decision
  • CRDL Strong Buy
  • AMTD
  • Analyst Count
  • CRDL 2
  • AMTD 0
  • Target Price
  • CRDL $9.00
  • AMTD N/A
  • AVG Volume (30 Days)
  • CRDL 781.9K
  • AMTD 56.6K
  • Earning Date
  • CRDL 11-13-2025
  • AMTD 04-30-2025
  • Dividend Yield
  • CRDL N/A
  • AMTD N/A
  • EPS Growth
  • CRDL N/A
  • AMTD N/A
  • EPS
  • CRDL N/A
  • AMTD 0.76
  • Revenue
  • CRDL N/A
  • AMTD $67,032,000.00
  • Revenue This Year
  • CRDL N/A
  • AMTD N/A
  • Revenue Next Year
  • CRDL N/A
  • AMTD N/A
  • P/E Ratio
  • CRDL N/A
  • AMTD $1.54
  • Revenue Growth
  • CRDL N/A
  • AMTD N/A
  • 52 Week Low
  • CRDL $0.77
  • AMTD $0.92
  • 52 Week High
  • CRDL $2.24
  • AMTD $1.67
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 44.27
  • AMTD 48.53
  • Support Level
  • CRDL $1.04
  • AMTD $1.22
  • Resistance Level
  • CRDL $1.16
  • AMTD $1.24
  • Average True Range (ATR)
  • CRDL 0.06
  • AMTD 0.07
  • MACD
  • CRDL 0.00
  • AMTD -0.02
  • Stochastic Oscillator
  • CRDL 18.00
  • AMTD 14.70

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About AMTD AMTD IDEA Group each representing six (6)

AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.

Share on Social Networks: